During the corresponding time, Sunshine Biopharma Inc saw a revenue deteriorated by -1.56 % year on year, sequentially revenue grew by 14.53 %. While revenue at the Sunshine Biopharma Inc 's corporate clients
Sunshine Biopharma Inc's Comment on Sales, Marketing and Customers
The company previously generated approximately 10% of its over-the-counter (OTC) product sales revenue from the United States and 90% from Canada before discontinuing U.S. sales operations. It operates in the Canadian generic pharmaceuticals market, which is valued at approximately $10.4 billion USD in 2024 and projected to grow to $19.7 billion USD by 2033. In the anti-coronavirus drug development sector, the company competes with U.S. firms including Pfizer, Merck, Gilead, Eli Lilly, and Regeneron, all of which have developed COVID-19 vaccines and treatments. In anticancer drug development, its competitors include Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb, and Novartis, as well as smaller companies. The company’s OTC products compete in a crowded market; its Essential•9™ supplement is noted as the only essential amino acid supplement containing all nine essential amino acids in capsule form. Customers and markets referenced in company filings include Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, Regeneron, and Roche.
Sunshine Biopharma Inc’s Comment on Sales, Marketing and Customers
The company previously generated approximately 10% of its over-the-counter (OTC) product sales revenue from the United States and 90% from Canada before discontinuing U.S. sales operations. It operates in the Canadian generic pharmaceuticals market, which is valued at approximately $10.4 billion USD in 2024 and projected to grow to $19.7 billion USD by 2033. In the anti-coronavirus drug development sector, the company competes with U.S. firms including Pfizer, Merck, Gilead, Eli Lilly, and Regeneron, all of which have developed COVID-19 vaccines and treatments. In anticancer drug development, its competitors include Merck, Amgen, Roche, Pfizer, Bristol-Myers Squibb, and Novartis, as well as smaller companies. The company’s OTC products compete in a crowded market; its Essential•9™ supplement is noted as the only essential amino acid supplement containing all nine essential amino acids in capsule form. Customers and markets referenced in company filings include Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, Regeneron, and Roche.
Sources:
Sunshine Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sunshine Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sunshine Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
